Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more
Location: 1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States | Website: https://www.savarapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.361B
52 Wk Range
$1.89 - $6.98
Previous Close
$6.69
Open
$6.69
Volume
715,955
Day Range
$6.65 - $6.88
Enterprise Value
1.268B
Cash
124.9M
Avg Qtr Burn
-24.82M
Insider Ownership
4.66%
Institutional Own.
83.53%
Qtr Updated
09/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Molgramostim Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | BLA Resubmission |